Glucagon Benefits: What Studies Report

Glucagon is a pancreatic hormone that acts on the glucagon receptor. In the peptide literature of the past decade, the phrase "glucagon benefits" rarely refers to the native hormone studied on its own. Instead, it usually refers to glucagon receptor agonism as one component of a multi-receptor molecule — for example a glucagon/GLP-1 dual agonist, or a GIP/GLP-1/glucagon triple agonist. This page organises, by outcome domain, what published studies measured and reported, with the study type and population attached to each finding, and it flags plainly where evidence is absent.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing below describes a protocol, and no outcome described here should be read as something a reader can expect.

What "glucagon" refers to in the published literature

Three distinct things get grouped under the same word, and separating them changes how the evidence reads:

• Native glucagon as a medicine. Glucagon products have a long-standing regulated role in emergency management of severe hypoglycaemia. That use is a regulatory and clinical-practice fact rather than a finding from the studies summarised on this page, and none of the papers cited here evaluated it.
• Glucagon receptor agonism inside a dual agonist. Survodutide combines glucagon receptor and GLP-1 receptor activity, and researchers tested it in a randomized phase 2 trial in metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis (PMID 38847460).
• Glucagon receptor agonism inside a triple agonist. Retatrutide engages GIP, GLP-1 and glucagon receptors, and review articles have summarised its obesity trial programme on that basis (PMID 40563436, PMID 40741227).

Because glucagon receptor activity in these molecules is bundled with incretin receptor activity, published trials cannot isolate how much of any reported effect belongs to the glucagon component. That attribution limit applies to every domain below.

Outcome domains at a glance

Liver: MASH and fibrosis

The most direct human evidence for a glucagon-receptor-containing peptide comes from a phase 2 randomized, double-blind, placebo-controlled trial of survodutide in adults with biopsy-confirmed MASH and fibrosis, in which researchers assigned participants to weekly subcutaneous survodutide at 2.4 mg, 4.8 mg or 6.0 mg or to placebo for 48 weeks (PMID 38847460). The study's primary histologic endpoint was improvement in MASH without worsening of fibrosis, and a higher proportion of participants receiving survodutide met that endpoint than those receiving placebo (PMID 38847460).

Two framing points matter. First, this was a phase 2 trial with a histologic surrogate endpoint, not a trial of liver-related clinical events such as decompensation or transplant. Second, the molecule tested was a dual glucagon/GLP-1 receptor agonist, so the trial does not establish what glucagon receptor agonism alone would do in the same population (PMID 38847460).

Body weight and body composition

For triple agonism, the evidence in this set is review-level rather than primary. A 2025 review of retatrutide in obesity pharmacotherapy summarised the reported weight-reduction findings from its trial programme and described the GIP/GLP-1/glucagon receptor mechanism (PMID 40563436). A separate 2025 review of triple-agonism-based therapies for obesity placed those agents alongside single and dual incretin approaches and discussed their reported metabolic effects (PMID 40741227).

For comparison, in agents acting at GLP-1 receptors without glucagon receptor activity, a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials in non-diabetic individuals with overweight or obesity reported greater weight loss with GLP-1 receptor agonists than with placebo (PMID 37661106). That comparator literature is substantially larger and more mature than the glucagon-containing literature, which is a reason the two are not interchangeable when readers assess certainty.

What was not measured

None of the verified papers reported body-composition outcomes attributable specifically to glucagon receptor activation, and none isolated energy expenditure as an endpoint of a glucagon-only intervention. Claims that glucagon "burns fat" independently of appetite or intake are not supported by any trial in this set; the available human data come from multi-receptor molecules whose contributions cannot be separated (PMID 40741227).

Glycaemic measures

Glucagon physiologically raises blood glucose, which is why glucose outcomes in glucagon-containing agonists are watched closely. The clearest glycaemic evidence in this verified set, however, concerns GLP-1 receptor agonists rather than glucagon agonism. PIONEER 1 was a randomized trial of oral semaglutide monotherapy at 3 mg, 7 mg and 14 mg compared with placebo over 26 weeks in people with type 2 diabetes, and the study reported greater HbA1c reduction with oral semaglutide than with placebo (PMID 31186300). Pooled insights from the SUSTAIN 1–7 programme described HbA1c and body-weight reductions with once-weekly subcutaneous semaglutide in type 2 diabetes (PMID 30615985). A phase 1 randomized, double-blind, placebo-controlled trial in healthy Chinese subjects characterised the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide (PMID 38808476).

These are included as context for what a mature glycaemic evidence package looks like. No trial in this verified set reported HbA1c outcomes for a glucagon-only intervention.

Cardiovascular and kidney domains

A 2025 systematic review and meta-analysis of 99,599 patients examined cardiovascular effects and tolerability of GLP-1 receptor agonists (PMID 40892610). A 2024 review discussed GLP-1 receptor agonists and kidney outcomes (PMID 39364792). Neither addressed glucagon receptor agonists, and this evidence set contains no dedicated cardiovascular or renal outcomes trial of a glucagon-containing peptide.

For scale, dedicated event-driven outcome programmes in cardiometabolic medicine are large and purpose-built: the ziltivekimab cardiovascular outcomes trial, an interleukin-6 inhibition study, published its rationale, design and baseline characteristics separately from any efficacy result (PMID 41369941). Nothing of comparable scope has reported for glucagon receptor agonism in the papers verified here.

Sleep apnoea and knee osteoarthritis

The TRIUMPH registrational programme set out the rationale and design for trials of retatrutide in obesity, obstructive sleep apnoea and knee osteoarthritis (PMID 41090431). A design paper states what will be measured; it does not report results. Readers encountering claims about glucagon-containing agents and apnoea severity or joint pain should note that, within this evidence set, those endpoints were defined rather than reported (PMID 41090431).

Claims with weak or absent evidence in this set

• Glucagon as a standalone weight-loss peptide. No randomized trial of glucagon alone for weight outcomes appears in the verified papers; the human weight data involve multi-receptor molecules reviewed at summary level (PMID 40563436).
• Glucagon for athletic performance, recovery or muscle preservation. No study in this set measured those endpoints.
• Glucagon for cognition, mood or longevity. Not evaluated in any cited paper.
• Cardiovascular risk reduction from glucagon agonism. The available meta-analysis covered GLP-1 receptor agonists, not glucagon agonists (PMID 40892610).
• Long-term safety of glucagon-containing agonists. The longest trial here ran 48 weeks in MASH (PMID 38847460); multi-year safety data were not reported.

Tolerability and Adverse Events: What Studies Report

In the phase 2 survodutide trial, researchers reported that adverse events including nausea, diarrhoea and vomiting occurred more frequently with survodutide than with placebo over the 48-week treatment period (PMID 38847460). Reviews of retatrutide similarly described gastrointestinal adverse events as the most commonly summarised tolerability issue across its obesity trials (PMID 40563436), and a review of triple agonism in obesity discussed tolerability alongside efficacy (PMID 40741227).

In the broader incretin class, the 2025 meta-analysis of 99,599 patients assessed tolerability as well as cardiovascular effects of GLP-1 receptor agonists (PMID 40892610), and a narrative review examined the question of GLP-1 receptor agonists and thyroid cancer (PMID 38343381). A phase 1 trial in healthy Chinese subjects evaluated safety and tolerability of oral semaglutide as a pre-specified objective (PMID 38808476). These safety signals belong to the agents studied and are not transferable to glucagon receptor agonism by analogy.

Limitations of the current evidence base

1. Attribution. Every human trial here that involved glucagon receptor activity used a molecule with additional incretin receptor activity (PMID 38847460).
2. Phase and endpoint maturity. The MASH evidence is phase 2 with a histologic endpoint (PMID 38847460), and the triple agonist evidence in this set is review-level or design-stage (PMID 41090431).
3. Population narrowness. Participants in these trials had defined conditions such as MASH with fibrosis or obesity; findings were not reported for healthy individuals (PMID 38847460).
4. Comparator borrowing. Much of what circulates as "glucagon benefits" online is in fact GLP-1 class data, such as the weight-loss meta-analysis in non-diabetic individuals with overweight or obesity (PMID 37661106).

Research-use-only materials sold for laboratory work are not approved medicines and have not been evaluated in the trials described above. Readers with questions about any of these compounds should raise them with a licensed clinician.

References

• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (The New England Journal of Medicine, 2024)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Triple Agonism Based Therapies for Obesity (Current Cardiovascular Risk Reports, 2025)
• The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials (The American Journal of Clinical Nutrition, 2023)
• PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes (Diabetes Care, 2019)
• Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials (Diabetes & Metabolism, 2019)
• A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects (Diabetes, Obesity & Metabolism, 2024)
• Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients (Journal of the American College of Cardiology, 2025)
• Glucagon-like peptide-1 receptor agonists and kidney outcomes (Journal of Diabetes, 2024)
• Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (Thyroid, 2024)
• Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction (JAMA Cardiology, 2026)